MiNK Therapeutics Inc INKT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INKT is a good fit for your portfolio.
News
-
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
-
MiNK Reports Fourth Quarter and Year-End 2023 Results
-
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
-
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
-
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
-
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
-
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
Trading Information
- Previous Close Price
- $0.87
- Day Range
- $0.88–0.93
- 52-Week Range
- $0.75–3.34
- Bid/Ask
- $0.90 / $0.97
- Market Cap
- $32.18 Mil
- Volume/Avg
- 32,366 / 102,034
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.48%
Company Profile
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 37
- Website
- https://www.minktherapeutics.com
Comparables
Valuation
Metric
|
INKT
|
ITOS
|
VOR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.67 | 0.76 |
Price/Sales | — | 30.67 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
INKT
ITOS
VOR
Financial Strength
Metric
|
INKT
|
ITOS
|
VOR
|
---|---|---|---|
Quick Ratio | 0.30 | 13.46 | 8.81 |
Current Ratio | 0.32 | 13.76 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
INKT
ITOS
VOR
Profitability
Metric
|
INKT
|
ITOS
|
VOR
|
---|---|---|---|
Return on Assets (Normalized) | −151.68% | −12.92% | −41.83% |
Return on Equity (Normalized) | — | −14.67% | −51.69% |
Return on Invested Capital (Normalized) | — | −18.54% | −47.03% |
Return on Assets
INKT
ITOS
VOR
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qlhjktlg | Bkm | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Crqdsxcws | Zsqpn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xgbvzdsx | Fjxpyw | $97.8 Bil | |
MRNA
| Moderna Inc | Mzztnqh | Qlbh | $41.3 Bil | |
ARGX
| argenx SE ADR | Jrppfnrj | Dmrw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qgqtfxd | Sbylc | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gcmtbcjh | Jsfjdct | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xvykychvh | Jqrccf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xdtdzrqgmt | Hcprqp | $12.5 Bil | |
INCY
| Incyte Corp | Ggplqdrh | Jmvstrw | $11.6 Bil |